BPC-157 and TB-500 are the two most popular "recovery" peptides in fitness circles, and they are constantly compared — and often stacked. Despite the pairing, they are different molecules with different origins: BPC-157 is a synthetic fragment derived from a protein in gastric juice, studied mainly for tendon, ligament and gut healing; TB-500 is a synthetic version of a region of Thymosin Beta-4, a protein involved in cell migration and broad tissue repair. They share something important too: both rest almost entirely on animal studies, neither has completed human clinical trials, and both are unapproved and banned in sport.
At a glance
| BPC-157 | TB-500 | |
|---|---|---|
| Derived from | A protein in gastric juice (Body Protection Compound) | Thymosin Beta-4 (actin-regulating protein) |
| Studied mainly for | Tendon, ligament & gut healing | Cell migration & broad tissue repair |
| Evidence base | Animal studies; no completed human trials | Animal studies; no completed human trials |
| FDA status | Not approved (research chemical) | Not approved (research chemical) |
| Sport status | Banned (WADA) | Banned (WADA) |
| Human safety data | Not established | Not established |
The bottom line
Bottom line: These are distinct peptides studied for overlapping goals — BPC-157 leans toward localized tendon/gut repair, TB-500 toward systemic cell-migration-driven repair. The honest comparison, though, is that both are unproven in humans: the encouraging results are from rodents, neither is FDA-approved, and both are prohibited in sport. Marketing that presents either as an established "healing" therapy is ahead of the evidence.
Frequently asked questions
What is the difference between BPC-157 and TB-500?
BPC-157 is derived from a gastric-juice protein and is studied mostly for tendon and gut healing, while TB-500 is a synthetic fragment of Thymosin Beta-4 studied for cell migration and broad tissue repair. They are different molecules with different proposed mechanisms.
Can you stack BPC-157 and TB-500 together?
They are commonly combined in fitness use because their proposed mechanisms differ, but there is no human trial evidence supporting the safety or benefit of either alone or together. Both are unapproved research chemicals.
Are BPC-157 and TB-500 proven to work in humans?
No. Both are supported almost entirely by animal studies, with no completed published human clinical trials. Their effectiveness and safety in people remain unproven, and both are banned in sport.
Are BPC-157 and TB-500 legal?
Neither is FDA-approved for human use; they are sold as research chemicals. Both are also prohibited at all times under the World Anti-Doping Agency code.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. Peer-reviewed study
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. Peer-reviewed study
- Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-eNOS pathway. Sci Rep. 2020. Peer-reviewed study
- Józwiak M, Bauer M, Kamysz W, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025. Peer-reviewed study
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019. Peer-reviewed study
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. Peer-reviewed study
- Philp D, Kleinman HK. Animal studies with thymosin beta-4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 2010. Peer-reviewed study
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. Peer-reviewed study
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci. 2024. Peer-reviewed study
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. Peer-reviewed study
- Judák P, Van Eenoo P, Deventer K. Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5. Anal Biochem. 2017. Peer-reviewed study
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. Peer-reviewed study